



## Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March

March 7, 2018

BOSTON, March 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will present a corporate update at two investor conferences in March:

### **Cowen and Company 38<sup>th</sup> Annual Health Care Conference**

**Date:** Wednesday, March 14, 2018

**Time:** 10:40 a.m. ET

**Location:** Boston, MA

### **17<sup>th</sup> Annual Needham Healthcare Conference**

**Date:** Wednesday, March 28, 2018

**Time:** 1:30 p.m. ET

**Location:** New York, NY

Live audio webcasts of both presentations will be available under "Events & Presentations" in the Investors & Media section of the Company's website at [www.rhythmtx.com](http://www.rhythmtx.com). Replays of the webcasts will be available on the Rhythm website for 30 days following each presentation.

### **About Rhythm**

Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm's lead product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Rhythm also supports The Genetic Obesity Project ([www.GeneticObesity.com](http://www.GeneticObesity.com)), which is dedicated to improving the understanding of severe obesity that results from specific genetic disorders. The company is based in Boston, MA.

### **Investor Contact:**

Hannah Deresiewicz  
Stern Investor Relations, Inc.  
212-362-1200  
[hannahd@sternir.com](mailto:hannahd@sternir.com)

### **Media Contact:**

Adam Daley  
Berry & Company Public Relations  
212-253-8881  
[adaley@berrypr.com](mailto:adaley@berrypr.com)



Rhythm Pharmaceuticals, Inc.